A5110619508- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Acute Myeloid Leukemia Research
- Chronic Myeloid Leukemia Treatments
- Kruppel-like factors research
- Eosinophilic Disorders and Syndromes
- Acute Lymphoblastic Leukemia research
- Hemoglobinopathies and Related Disorders
- Cancer Genomics and Diagnostics
- Multiple Myeloma Research and Treatments
- Histone Deacetylase Inhibitors Research
- Chronic Lymphocytic Leukemia Research
- Protein Degradation and Inhibitors
- Platelet Disorders and Treatments
- Biomarkers in Disease Mechanisms
- Hematopoietic Stem Cell Transplantation
- Monoclonal and Polyclonal Antibodies Research
- Cytokine Signaling Pathways and Interactions
- Cancer-related molecular mechanisms research
- Circular RNAs in diseases
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Neutropenia and Cancer Infections
- Retinoids in leukemia and cellular processes
- Long-Term Effects of COVID-19
- Mast cells and histamine
- Quinazolinone synthesis and applications
Ospedale Papa Giovanni XXIII
2016-2025
Ospedale Maggiore
2021
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico
2021
University of Milano-Bicocca
2020
University of Bergamo
2008-2016
Azienda Ospedaliero Universitaria Ospedali Riuniti
2007-2012
A phase II study was conducted to evaluate the safety and efficacy of Givinostat, a novel Histone-Deacetylases inhibitor, in patients with Polycythaemia Vera (PV, n = 12), Essential Thrombocythaemia (ET, 1) Myelofibrosis (n 16), bearing JAK2V617F mutation. The approved by local ethics committees all human participants gave written informed consent. Givinostat given orally for 24 weeks at starting dose 50 mg twice daily. median treatment duration 20 weeks. Reasons discontinuation were disease...
We tested the hypothesis that levels of pentraxin high sensitivity C-reactive protein and 3 might be correlated with cardiovascular complications in patients essential thrombocythemia polycythemia vera. High were measured 244 consecutive vera whom, after a median follow up 5.3 years (range 0–24), 68 events diagnosed. The highest tertile was compared lowest (>3 vs.
Transformation to secondary myelofibrosis (MF) occurs as part of the natural history polycythemia vera (PPV‐MF) and essential thrombocythemia (PET‐MF). Although primary (PMF) MF are considered similar diseases managed similarly, there few studies specifically focused on latter. The aim this study was characterize mutation landscape, describe main clinical correlates prognostic implications mutations, in a series 359 patients with PPV‐MF PET‐MF. Compared PV ET, JAK2 V617F CALR mutated allele...
Abstract The platelet contribution to the thrombophilic state of patients with myeloproliferative neoplasms (MPNs), i.e., essential thrombocythemia (ET) and polycythemia vera (PV), remains uncertain. In this study we aimed characterize thrombin generation (TG) potential expressed by platelets from these subjects, compare it normal platelets, identify what factors might be responsible for TG. a group 140 MPN (80 ET 60 PV) 72 healthy subjects measured global procoagulant rich plasma (PRP)...
We analyzed FcgammaRIIIA-158V/F and FcgammaRIIA-131H/R polymorphisms in a cohort of 94 newly diagnosed follicular lymphoma (FL) patients sequentially treated with CHOP Rituximab. With median follow-up 5.8 years, the overall survival at 8 years is 83%. Univariate multivariate analysis showed no correlation between FcgammaRIIIA-158VV/VF FcgammaRIIA-131HH/HR response rate, molecular event-free obtained after By contrast, achievement durable clearance BCL2/IgH+ cells detectable bone marrow...
The driver mutations JAK2V617F, MPLW515L/K and CALR influence disease phenotype of myeloproliferative neoplasms (MPNs) might sustain a condition chronic inflammation. Pentraxin 3 (PTX3) high-sensitivity C-reactive protein (hs-CRP) are inflammatory biomarkers potentially useful for refining prognostic classification MPNs. We evaluated 305 with essential thrombocythemia (ET) 172 polycythemia vera (PV) patients diagnosed according to the 2016 WHO criteria full molecular characterization...
The prognostic significance of bone marrow (BM) fibrosis grade in patients with primary myelofibrosis (PMF) is still debated. A greater than 1 was shown to associate higher risk death, and addition IPSS score resulted a more accurate prediction survival. aim this study analyze the impact BM 490 PMF, evaluated at diagnosis, molecularly annotated extensive follow-up information. We found that 2 on 0-3 scale associated clinical characteristics indicative advanced disease, such as anemia,...
<title>Abstract</title> We report an in-depth retrospective analysis of updated series 30 subjects with clonal megakaryocyte dysplasia normal blood values (CMD-NBV). Sixteen were men, median age was 47.5 years (IQR, 39–53 years). A thrombosis-driven situational diagnosis (69% subjects), high incidence thrombotic events (6.5 x 100 subject-years), and indolent disease progression (one case only progressed towards active disease) the hallmarks CMD-NBV. Nineteen (63%) had a body mass index (BMI)...
Primary myelofibrosis (PMF) is a myeloproliferative neoplasm characterized by hyperplastic megakaryopoiesis and myelofibrosis. We recently described the upregulation of MAF (v-maf avian musculoaponeurotic fibrosarcoma oncogene homolog) in PMF CD34+ hematopoietic progenitor cells (HPCs) compared to healthy donor. Here we demonstrated that also upregulated with essential thrombocytemia (ET) polycytemia vera (PV) HPCs. overexpression knockdown experiments shed some light into role pathogenesis,...
Background The identification of the JAK2V617F mutation is mandatory in diagnostic work-up Philadelphia chromosome-negative myeloproliferative neoplasms. Several molecular techniques to detect this are currently available, but each them has some limits.Design and Methods We set up a novel method for based on an allele-specific loop-mediated amplification, not polymerase chain reaction analysis. This innovative technique amplifies DNA targets under isothermal conditions with high specificity,...